| Recruiting | Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients Wit PIK3CA-Related Overgrowth Spectrum (PROS), PIK3CA-related Vascular Malformations (PRVM) | Phase 1 / Phase 2 | 2023-08-22 |
| Recruiting | Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL) | Phase 1 / Phase 2 | 2022-07-27 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Ca Ovarian Cancer, Recurrent Cancer | Phase 2 | 2021-10-11 |
| Terminated | First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2021-04-08 |
| Unknown | Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- A Advanced Breast Cancer | Phase 1 | 2021-04-01 |
| Completed | Single Dose Glumetinib in Healthy Chinese Male Subjects Healthy Volunteers | Phase 1 | 2021-03-02 |
| Terminated | Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Ovarian Cancer, Breast Cancer, Solid Tumor | Phase 1 | 2020-09-28 |
| Recruiting | Evaluate the Safety and Clinical Activity of HH2853 FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma | Phase 1 / Phase 2 | 2020-09-08 |
| Terminated | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors Advanced Tumors, Melanoma, Non-Small-Cell Lung Cancer | Phase 1 / Phase 2 | 2020-01-07 |
| Unknown | Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Pa Negative T790M Mutation and Met Amplification | Phase 1 / Phase 2 | 2019-11-18 |
| Unknown | This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Pat Extensive-stage Small Cell Lung Cancer | Phase 2 / Phase 3 | 2019-11-14 |
| Recruiting | Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer C-Met Exon 14 Mutation | Phase 1 / Phase 2 | 2019-07-15 |
| Completed | Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33 Advanced Solid Tumors | Phase 1 | 2018-07-05 |
| Completed | A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors Advanced Solid Tumor | Phase 1 | 2017-12-16 |
| Completed | Study to Evaluate the Safety and Anti-tumor Activity of SCC244 Advanced Solid Tumor | Phase 1 | 2017-09-14 |
| Unknown | Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810 Advanced Solid Tumor, Advanced/Metastatic Colorectal Cancer | Phase 1 | 2017-08-31 |
| Unknown | Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherap Advanced Solid Tumor, Advanced/Metastatic Colorectal Cancer | Phase 1 | 2016-10-01 |
| Completed | Study of the AL3810 in the Treatment of Advanced Solid Tumor Advanced Solid Tumors | Phase 1 | 2014-03-01 |
| Completed | Study of Simmitecan Hydrochloride in the Treatment of Advanced Solid Tumor Advanced Solid Tumor | Phase 1 | 2012-12-01 |